ArticleMolecular biology reports2025
Combined effects of IRAK inhibition and pioglitazone on hepatic inflammation and apoptosis in a mouse model of MASLD.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex differences in MASLD-related atherosclerosis: plaque phenotype, vascular dysfunction, and cardiovascular outcomes.Biology of sex differences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundInflammation and apoptosis play crucial role in the progression of liver diseases. This study aimed to evaluate the effects of Interleukin-1 receptor-associated kinase inhibitor (IRAKi) in combination with pioglitazone on the expression of inflammatory and apoptotic markers in the liver of C57BL/6J mice subjected to a high-fat diet (HFD).
methodsMale C57BL/6J mice were divided into five groups: Control (normal diet, ND), HFD, HFD-IRAKi, HFD-pioglitazone (HFD-PIO), and HFD-IRAKi-PIO. All groups, except ND, were administered HFD for 12 weeks. Subsequently, IRAKi (2 mg/kg, intraperitoneally, three times per week) and pioglitazone (10 mg/kg, orally, daily) were administered for 14 days. Gene and protein expression levels were assessed using real-time PCR and western blot analysis.
resultsSeparate administration of IRAKi and pioglitazone significantly reduced the mRNA levels of inflammatory markers IL-1β, IL-6, TNF-α, and NF-κB (p < 0.001). Combined treatment with IRAKi and pioglitazone significantly reduced hepatic triglyceride (TG) and cholesterol content (p < 0.05) and attenuated expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, NF-κB) and apoptotic markers (cleaved-CASPASE3, Bax), while enhancing Il10 expression. These findings support the therapeutic potential of this combination in metabolic liver diseases such as MASLD.
conclusionCo-administration of IRAKi and PIO attenuated markers of inflammation and apoptosis. These findings highlight the potential of IRAKi and pioglitazone as therapeutic agents for metabolic and inflammatory liver diseases, warranting further clinical evaluation.
Indexed as
Identifiers
40493096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.